CN1520881A - Sterilizing preparation for preventing and curing bovine mastitis and preparing process thereof - Google Patents
Sterilizing preparation for preventing and curing bovine mastitis and preparing process thereof Download PDFInfo
- Publication number
- CN1520881A CN1520881A CNA031153887A CN03115388A CN1520881A CN 1520881 A CN1520881 A CN 1520881A CN A031153887 A CNA031153887 A CN A031153887A CN 03115388 A CN03115388 A CN 03115388A CN 1520881 A CN1520881 A CN 1520881A
- Authority
- CN
- China
- Prior art keywords
- preparation
- biocide preparation
- biocide
- addressed
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 99
- 208000031462 Bovine Mastitis Diseases 0.000 title claims description 12
- 238000000034 method Methods 0.000 title description 7
- 230000001954 sterilising effect Effects 0.000 title description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 28
- 210000000481 breast Anatomy 0.000 claims abstract description 26
- 239000003381 stabilizer Substances 0.000 claims abstract description 12
- 230000003115 biocidal effect Effects 0.000 claims description 74
- 239000003139 biocide Substances 0.000 claims description 65
- 102000016943 Muramidase Human genes 0.000 claims description 22
- 108010014251 Muramidase Proteins 0.000 claims description 22
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 22
- 229960000274 lysozyme Drugs 0.000 claims description 22
- 239000004325 lysozyme Substances 0.000 claims description 22
- 235000010335 lysozyme Nutrition 0.000 claims description 22
- 241000191940 Staphylococcus Species 0.000 claims description 19
- 241000283690 Bos taurus Species 0.000 claims description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 18
- 235000013336 milk Nutrition 0.000 abstract description 18
- 239000008267 milk Substances 0.000 abstract description 18
- 210000004080 milk Anatomy 0.000 abstract description 18
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 17
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 14
- 241000894006 Bacteria Species 0.000 abstract description 10
- 230000002147 killing effect Effects 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 108090000988 Lysostaphin Proteins 0.000 abstract description 2
- 241000194017 Streptococcus Species 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 41
- 230000000694 effects Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 241000186064 Trueperella pyogenes Species 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 241000193985 Streptococcus agalactiae Species 0.000 description 9
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 9
- 241000194054 Streptococcus uberis Species 0.000 description 9
- 244000052616 bacterial pathogen Species 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 9
- 229940115922 streptococcus uberis Drugs 0.000 description 9
- 238000010171 animal model Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 210000005075 mammary gland Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000249 desinfective effect Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229940030998 streptococcus agalactiae Drugs 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 4
- 108010036991 bis(N-succinyl-glutamyllysin)hexamethylenediamine Proteins 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 4
- 208000004396 mastitis Diseases 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100040907 Glycerol kinase 3 Human genes 0.000 description 2
- 101710181614 Glycerol kinase 3 Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940023064 escherichia coli Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000000009 lactational effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 241000974485 Aricia shasta Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- -1 alcohol ester Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention discloses one kind of bactericidal preparation containing antibacterial peptide, lysostaphin enzyme and stabilizer. The present invention discloses also the preparation process of the bactericidal preparation and its application in treating and preventing milk cow's udder infection. The bactericidal preparation may be injected in udder or loaded onto carrier for being applied to udder. The bactericidal preparation can kill various bacteria likely causing milk cow's udder infection, especially colibacillus, staphylococcus aureus, streptococcus and pyogenic corynebacteria, with killing rate as high as 99 %, and can treat and cure milk cow's inflammation of udder.
Description
Technical field
The present invention relates to a kind of biocide preparation, relate in particular to a kind of biocide preparation that contains antibacterial peptide in order to the control bovine mastitis.
Background technology
Dairy and milk foods processing industry are the important symbols of animal husbandry level, and bovine mastitis is the main difficult problem of puzzlement dairy development always.The incidence rate of China's bovine mastitis reaches 20-70%, and indivedual cows sickness rate are higher.The economic loss that bovine mastitis causes comprises that veterinary treatment cost is high, output descends, milch cow is eliminated too early, milk quality difference etc.Bovine mastitis is by staphylococcus aureus, bacterial infection such as escherichia coli and streptococcus causes, often treating cow mammary gland with the antibiotic (as penicillin, streptomycin, gentamycin, chloromycetin, neomycin etc.) of heavy dose both at home and abroad infects, though antibiotic has certain curative effect, but because above-mentioned pathogenic bacterium have mostly produced endurance strain, therefore, curative effect and not obvious.Cause antibiotic remains in the milk on the contrary, it is serious that the milk that these cattle produced is sneaked into the consequence that edible milk causes.FAO (Food and Agriculture Organization of the United Nation) (FAO) and The World Health Organization (WHO) all advise, the milk of extruding at least 3 days after milch cow is accepted the antibiotic therapy drug withdrawal is not directly as edible milk material (preferably taking drug withdrawal 5-7 days).And tackle mastitis at present in the world except using antibiotic not to have its medicine.
Therefore, efficient, the safe present antibiotic that generally uses of new drug replacement of development is the important topic of preventing and treating bovine mastitis.
U.S. Pat 5762948 discloses the wet tissue of a kind of prevention and the infection of treatment cow mammary gland, and its composition is aided with other antimicrobial components such as ethanol based on a kind of antibacterial peptide nisin.This wet tissue can be removed the various pathogenic bacterium that cause intramammary infection, but to the DeGrain of drug resistance staphylococcus aureus.
Summary of the invention
One of technical issues that need to address of the present invention provide a kind of biocide preparation that is used to prevent and treat bovine mastitis, to overcome the above-mentioned defective that prior art exists.
Another technical problem that the present invention need solve provides a kind of preparation method of biocide preparation.
Another technical problem that the present invention need solve discloses the application of described biocide preparation in the medicine of preparation treatment bovine mastitis.
Inventive concept of the present invention is such:
Antibacterial peptide is the micromolecule polypeptide of a kind of biologically active of organism through inducing generation, generally is made up of 20-60 aminoacid, and molecular weight is about 2000-7000D.Along with Medical Immunology and molecular biological developing rapidly, the research of antibacterial peptide more and more becomes the heat subject in biotechnology and the biomedicine field.Up to now, found to surpass more than 200 kind of antibacterial peptide on many animals (especially insecticide), plant, microorganism and human body, this class small peptide not only has the broad-spectrum bactericidal action to antibacterial, fungus, and virus, protozoon and cancerous cell are also had attack function.Clinical trial also shows, maybe may cause under the situation of courses of infection the organism infection pathogenic bacteria, and antibiotic Toplink is killed the pathogenic bacteria of having invaded fast, and can stop pathogenic bacteria continue infect.
Enzyme with bactericidal action, staphylococcus lysozyme (lysostaphin) particularly, a kind of zinciferous metalloproteases, the glycine peptide bond of single-minded degradation of cell wall, the cell wall of gram positive bacterias such as energy cracking staphylococcus aureus, thereby play the purpose of thorough killing bacteria, be difficult for to produce drug resistance, especially the effect of the pathogenic bacterium that drug resistance staphylococcus aureus etc. is difficult to eradicate is very good.
The inventor carries out antibacterial peptide GK and staphylococcus lysozyme composite, antibacterial peptide GK has killing action to gram positive bacteria and gram negative bacteria, widened fungicidal spectrum, the pathogenic bacterium that drug resistance staphylococcus aureus etc. is difficult to eradicate have been had the good sterilization effect and add staphylococcus lysozyme.Two kinds all belong to protein, do not stimulate also can not produce any toxic and side effects, because production cost is low, the charge is small simultaneously.
Eliminate and the control cow mammary gland infects effectively that way is to kill the various antibacterials that cause infection, the various pathogenic bacterium in breast district particularly not only cause and self intramammary infection also can infect the milch cow to other simultaneously.The inventor is through test of many times, and antibacterial peptide GK and staphylococcus lysozyme is composite by a certain percentage, and the various pathogenic bacterium of killing milk Lac Bovis seu Bubali district that can be simple and effective are eliminated and infect, and can also play the effect of recurring and preventing of preventing simultaneously.
Technical scheme of the present invention is such:
A kind of biocide preparation, comprise one or more the antibacterial peptide GK and the enzyme of antimicrobial effective amount, the enzyme of being addressed comprises one or more in lysozyme or the staphylococcus lysozyme, the content of staphylococcus lysozyme is counted 0.0001～0.1wt% with total amount, and the content of the antibacterial peptide of being addressed is 0.0001～0.01wt%; Described biocide preparation also comprises stabilizing agent, and the stabilizing agent of being addressed is a kind of in Polyethylene Glycol or the chitosan, and content is 1～15%.
A kind of biocide preparation comprises staphylococcus lysozyme 0.0001～0.1wt%, antibacterial peptide GK0.0001～0.01wt%, stabilizing agent 1～15wt%, surfactant 0.1～0.5wt%, water surplus.
Relevant antibacterial peptide GK sees the patent of invention that the inventor declared JIUYUE in 2002 on the 2nd for details, and denomination of invention is one to be combined into antibacterial peptide, and application number is 02136766.3.
The main effect of stabilizing agent is to keep enzyme and the stability of antibacterial peptide under aqueous solution state, promptly keeps their activity.
The preparation method of the biocide preparation of being addressed comprises the steps:
Take by weighing enzyme, antibacterial peptide GK according to the above ratio, stabilizing agent mixes with water.
Preparation of the present invention is used to prepare the medicine for the treatment of bovine mastitis, can intramammary injection, and its dosage can be according to age, the state of an illness decision of milch cow, is generally twice of every day.The various antibacterials that cause that cow mammary gland infects be can kill, gram negative bacteria and gram positive bacteria comprised.Particularly escherichia coli, staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis and corynebacterium pyogenes.Can treat by these bacterial various mastitis.
Also above-mentioned biocide preparation can be carried on the carrier, carrier comprises non-woven material or cotton cloth, and it is forward and backward by smearing or wiping milk Lac Bovis seu Bubali district to be used to give milk, and carries out disinfection the cleaning in assurance breast district, minimizing possibility of infection.
Biocide preparation is tested by extracorporeal disinfecting, prove its The main pathogenic fungi to causing that cow mammary gland infects: the bactericidal effect of escherichia coli, staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis, corynebacterium pyogenes is very good, and killing rate is all above 99%.
Biocide preparation shows that to the The acute toxicity tests of Kunming white mice the animal via intramuscular injection is after 7 days, and no abnormal reaction, activity are normally.Observed through 7 days, 60 white mice all survive.The proof free of toxic effects.
Biocide preparation is to the test of SD rat vagina mucosa irritation, and standards of grading scoring and skin irritation strength grading with reference to skin irritation response strength in the disinfection technology standard (third edition) 1999.11 carry out the evaluation to the vaginal mucosa stimulus intensity.The result shows that biocide preparation is 0 to the highest total mark average of rat vagina mucosa irritation reaction, belongs to nonirritant.
Biocide preparation is to the therapeutic test of breast district actute infection, and in contrast with scotcil and streptomycin, after the administration 7 days, the result shows, biocide preparation can effectively be killed the various pathogen that cause intramammary infection, especially effective especially to staphylococcus aureus, two kinds of antibiotic then can not effectively be removed the pathogen in breast district.
The test of biocide preparation prevention intramammary infection, as can be seen, the biocide preparation Lac Bovis seu Bubali district that can effectively prevent to suckle is subjected to bacterial infection, can keep the cleaning in breast district.
The specific embodiment
Embodiment 1
The preparation of bactericidal wet tissue
1. prepare the 100g biocide preparation, staphylococcus lysozyme content 0.001g (0.001wt%) wherein, antibacterial peptide GK-2 (seeing that application number is 02136766.3 application for a patent for invention file) content 0.001g (0.001wt%), polyethyleneglycol content 3g (3%), water surplus.
2. to desktop, instrument, vessel, mixer sterilization.
3. on electronic balance, accurately take by weighing staphylococcus lysozyme, antibacterial peptide GK-2, Polyethylene Glycol, place mixer, add water 76.80g in proportion, stir, and be heated to 60 ℃ of dissolvings, be required biocide preparation.
Embodiment 2
The test of biocide preparation extracorporeal disinfecting
1, the preparation of test specimen:
(1) biocide preparation: press the method preparation of embodiment 1, staphylococcus lysozyme content 0.001wt% wherein, antibacterial peptide GK-2 content 0.001wt%, polyethyleneglycol content 3%.
(2) control formulation: wherein polyethyleneglycol content 3%.
The preparation of (1) (2) is carried out following processing: non-woven fabrics is cut into 8cm * 8cm, after 20 minutes, immerses in the above-mentioned solution, pull out after waiting to soak into, drip and go redundant solution, can use through ultraviolet disinfection.
2, test strain: staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis, escherichia coli and corynebacterium pyogenes (above bacterial strain comes from the military region, Shenyang army horse study on prevention institute).
3, test procedure:
(1) cultured test strain is washed fresh inclined-plane with 1% peptone PBS, and be diluted to suitable concentration, at 107～108cfu/ml.
(2) sample formulation and control formulation are made 1 * 3cm size, and be placed in the aseptic plate.
(3) get 20ul bacterium drop and be added on the preparation, smear evenly and pick up counting simultaneously.
(4) the preparation input is contained in the test tube of 5ml nertralizer with aseptic nipper after affacting the scheduled time, mixing fully vibrates.
(5) control formulation drops into the nertralizer test tube, fully does suitable dilution after the vibration.
(6) get whole liquid 0.5ml and carry out pour plate, 37 constant temperature are inverted and were cultivated 48 hours.
(7) calculate contrast and reclaim bacterium amount and sample recovery bacterium amount, draw killing rate.
4, result of the test
Table 1: bactericidal wet tissue extracorporeal disinfecting test killing rate result
Test strain biocide preparation control formulation
Escherichia coli 99.92% 0
Staphylococcus aureus 99.98% 0
Streptococcus agalactiae 99.92% 0
Streptococcus dysgalactiae 99.97% 0
Streptococcus uberis 99.56% 0
Corynebacterium pyogenes 99.46% 0
Embodiment 3
The test of biocide preparation extracorporeal disinfecting
1, the preparation of test specimen:
(1) biocide preparation sample: press the method preparation of embodiment 1, staphylococcus lysozyme content 0.001wt% wherein, antibacterial peptide GK-3 content 0.001wt%, polyethyleneglycol content 3%.
(2) control formulation: wherein polyethyleneglycol content 3%.
2, test strain: staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis, escherichia coli and corynebacterium pyogenes (above bacterial strain comes from the military region, Shenyang army horse study on prevention institute).
3, test procedure: undertaken by embodiment 2.
4, result of the test
Table 2: biocide preparation extracorporeal disinfecting test killing rate result
Test strain biocide preparation control formulation
Escherichia coli 99.95% 0
Staphylococcus aureus 99.97% 0
Streptococcus agalactiae 99.95% 0
Streptococcus dysgalactiae 99.98% 0
Streptococcus uberis 99.62% 0
Corynebacterium pyogenes 99.67% 0
Embodiment 4
Acute toxicity test in the animal body
1, the preparation of sample: press among the embodiment 1 method preparation biocide preparation wherein: staphylococcus lysozyme content 0.01wt% wherein, antibacterial peptide GK-1 content 0.001wt%, polyethyleneglycol content 5%.
2, experimental animal: adopt 60 of Kunming white mice, male and female half and half, body weight 33.5 ± 0.25g is provided by laboratory animal portion of Fudan University.
3, test method: observed animal toxic reaction under maximal dose through the intramuscular injection white mice in continuous once a day 7 days.
Experimental result shows that the animal via intramuscular injection is after 7 days, and no abnormal reaction, activity are normally.Observed through 7 days, 60 white mice all survive.The proof free of toxic effects.
Embodiment 5
Biocide preparation is to experimental animal vaginal mucosa irritant test
1, sample preparation: the preparation method of biocide preparation is with reference to embodiment 1, wherein: staphylococcus lysozyme content 0.01wt% wherein, antibacterial peptide GK-3 content 0.011wt%, polyethyleneglycol content 5%.
2, experimental animal: the SD rat, female, regular grade, 18, body weight 230 grams-250 grams divide three groups at random, and biocide preparation group, vehicle group and blank group, are provided by laboratory animal portion of Fudan University by 6 every group.
3, test method: with reference to 3.8 in the disinfection technology standard (third edition) 1999.11.Biocide preparation is put the animal intravaginal, contact 4 hours with vaginal mucosa.Vehicle group is soaked with sterile saline with cotton sliver 0.01 gram and is done same test.The blank group is left intact.Put to death animal in 24 hours, take out local vagina tissue, observation has or not hyperemia, edema phenomenon.Standards of grading scoring and skin irritation strength grading with reference to skin irritation response strength in the disinfection technology standard (third edition) 1999.11 carry out the evaluation to the vaginal mucosa stimulus intensity.
4, result of the test:
Table 3: biocide preparation is to experimental animal vaginal mucosa irritant test
The irritant reaction scoring
Group number of animals (only)
Erythema edema total points
Biocide preparation group 6000
Vehicle group 6000
Blank group 6000
Biocide preparation is 0 to the highest total mark average of rat vagina mucosa irritation reaction, belongs to nonirritant.
Embodiment 6
Biocide preparation is to the therapeutic test of breast district actute infection
1, sample is prepared
The preparation of biocide preparation: preparation method is pressed embodiment 1, staphylococcus lysozyme content 0.008wt% wherein, antibacterial peptide GK content 0.002wt%, polyethyleneglycol content 2%.With G-6 sintered glass filter filtration sterilization, be sealed in the peace bottle, put in 4 refrigerators and preserve.
Scotcil: 800,000 units, North China Pharmaceutical Factory
Streptomycin sulfate: 1,000,000 units, North China Pharmaceutical Factory
2, the preparation of experimental animal
Select lactational 4-8 year green grass or young crops, prime of life high yield, Fresian, totally 20, acute intramammary infection causes inflammation,, its symptom is a mammary swelling, milk is unusual: grumeleuse is arranged, flocculus or flocculus is arranged later on.But do not have pain, do not have other symptom.Be divided into 4 groups at random, 1 group is a biocide preparation treatment group, and 2 groups are scotcil treatment group, and 3 groups are streptomycin treatment group, and 4 groups are the blank group.
3, testing program:
Experimental technique:
The treatment group: the 1st group is single administration in the biocide preparation treatment group, presses each trouble breast district of dosage of 40ml, once injects in the breast, 2,3 groups: every day sooner or later respectively once, after extracting breast, press penicillin 100,000 units, the intramammary injection administration of streptomycin 100,000 units.4 groups: matched group, do not carry out any treatment, administration 7 days.
4, observation index:
(1) recovery from illness: the symptom of clinical mastitis all disappears, and the breast tissue softness does not have grumeleuse in the milk, and the color of milk is with the same white at ordinary times.
Effectively: clinical mastitis symptom alleviates, and perhaps no longer worsens, and milk is normal, but mammary swelling does not have complete obiteration.
(2) bacteriological detection: separate, cultivate, identify to treating the forward and backward pathogen that infects the breast district, wherein because cow mammary gland infects based on escherichia coli, staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis, six kinds of antibacterials of corynebacterium pyogenes, so this detection test is based on above-mentioned six kinds of antibacterials.The concrete operations step is as follows:
A, sampling: carry out with conventional aseptic sampling, use the 10ml test tube, 5-7ml sweet milk is gathered in each breast district of every cattle, attention be that preceding 2-3 abandons breast not, perform labelling, the fast as far as possible 4 ℃ of refrigerators of putting into are preserved.
B, cultivation, separation: cultivate and carry out with routine, 37 ℃ of temperature, relative temperature is more than 50%.Used culture medium mainly contains: 7% sheep blood agar; The sheep soup agar that adds 1% aesculin; The but graceful agar in Pu; Sodium azide crystal violet blood agar; Meat stream culture medium etc.(above culture medium is from the military region, Shenyang army horse study on prevention institute)
C, evaluation
The evaluation of staphylococcus aureus: adopt test tube method and slide method to carry out, utilize citric acid rabbit plasma solidification experiments to measure.
Streptococcic evaluation: adopt the Camp test to carry out, the Camp test positive and the negative person of aesculin promptly is a streptococcus agalactiae, the Camp test positive and the positive person of aesculin promptly is a streptococcus uberis, it promptly is streptococcus dysgalactiae that Camp tests the also negative person of negative aesculin.
Colibacillary evaluation: adopt the U.S. blue culture medium separation and Culture in Yihong and carry out V, P test and M, R test, V, P test negative, and M, R test positive person and be escherichia coli.
The evaluation of corynebacterium pyogenes: adopt blood agar culture-medium to cultivate, after 36 hours, as see that the about 1-2cm of diameter is arranged, figure, projection, milky, smooth surface is glossy, and the petite person of β Qiong Xuequan occurs, is corynebacterium pyogenes.
5, result of the test
Table 4: biocide preparation is to the therapeutic test result of breast district actute infection
Biocide preparation group scotcil group streptomycin group blank group
Clinical recovery (number) 4210
Performance is (number) 1220 effectively
Cause of disease escherichia coli 99.8 97.1 92.2 0
Bacterium kills
The rate of going out
(％)
Staphylococcus aureus 99.8 63.3 43.2 0
Streptococcus agalactiae 99.5 85.2 86.3 0
Streptococcus dysgalactiae 99.3 78.2 86.4 0
Streptococcus uberis 99.1 88.6 91.3 0
Corynebacterium pyogenes 99.4 78.5 87.9 0
As can be seen from the above table, biocide preparation can effectively be killed the various pathogen that cause intramammary infection, and is especially effective especially to staphylococcus aureus, and two kinds of antibiotic then can not effectively be removed the pathogen in breast district.
Embodiment 7
The test of biocide preparation prevention intramammary infection
1, sample is prepared
The preparation of biocide preparation: preparation method is pressed embodiment 1, staphylococcus lysozyme content 0.002wt% wherein, antibacterial peptide GK-2 content 0.002wt%, polyethyleneglycol content 3%, poly-Mountain of Pear alcohol ester 20 content 0.2wt%.
Preparation is carried out following processing: non-woven fabrics is cut into 8cm * 8cm, after 20 minutes, immerses in the above-mentioned solution, pull out after waiting to soak into, drip and go redundant solution, can use through ultraviolet disinfection.
Iodophor solution: 100ml, Zhejiang Agricultural Univ.
Sample solution: 1% peptone, 0.5% sodium thiosulfate, 2% tween 80, the PBS of 0.5% lecithin, every pipe 10ml.
2, the preparation of experimental animal
Select lactational 4-8 year green grass or young crops, prime of life high yield, Fresian, normally do not have any infection symptoms, totally 3,1 group is a biocide preparation prevention group, and 2 groups are the iodophor group, and 3 groups are the blank group.
3, test method:
An aseptic cotton is wiped away the adhesional wetting sample solution adopt the breast district, detect the natural clump count of each sample of breast district.Behind the contiguous position of 1 group with the former sampling of biocide preparation wiping, 1 minute, 30 minutes, 2 hours, respectively adopt sample one time; 2 little group of methods are with 1 group, residual natural bacteria number after the detection effect, the natural bacteria killing rate before and after the calculating effect.
4, result of the test
Table 5: the result of the test that biocide preparation prevention breast district infects
Killing rate (%) biocide preparation group iodophor group blank group
After 1 minute 99.9 94.2 13.5
After 30 minutes 99.1 91.1 15.2
After 2 hours 98.4 62.3 14.6
From above-mentioned test as can be seen, the biocide preparation Lac Bovis seu Bubali district that can effectively prevent to suckle is subjected to bacterial infection, can keep the cleaning in breast district.
Claims (14)
1. a biocide preparation is characterized in that, comprises one or more the antibacterial peptide GK and the enzyme of antimicrobial effective amount.
2. biocide preparation according to claim 1 is characterized in that the enzyme of being addressed comprises one or more in lysozyme or the staphylococcus lysozyme.
3. biocide preparation according to claim 2 is characterized in that the content of the staphylococcus lysozyme of being addressed is counted 0.0001～0.1wt% with total amount.
4. biocide preparation according to claim 3 is characterized in that the content of the antibacterial peptide of being addressed is counted 0.0001～0.01wt% with total amount.
5. according to the arbitrary described biocide preparation of claim 1-4, it is characterized in that described biocide preparation also comprises stabilizing agent.
6. biocide preparation according to claim 5 is characterized in that, the stabilizing agent of being addressed is a kind of in Polyethylene Glycol or the chitosan.
7. biocide preparation according to claim 6 is characterized in that the stabiliser content of being addressed counts 1～15% with total amount.
8. a biocide preparation is characterized in that comprising antibacterial peptide GK0.0001～0.01wt%, staphylococcus lysozyme 0.0001～0.1wt%, stabilizing agent 1～15wt%, water surplus.
9. the preparation method of a biocide preparation is characterized in that comprising the steps:
Take by weighing enzyme, antibacterial peptide GK in proportion, stabilizing agent mixes with water.
10. the preparation method of biocide preparation according to claim 9 is characterized in that, the enzyme of being addressed comprises one or more in lysozyme or the staphylococcus lysozyme.
11. the preparation method of biocide preparation according to claim 9 is characterized in that, the stabilizing agent of being addressed is a kind of in Polyethylene Glycol or the chitosan.
12. according to the application of the arbitrary described biocide preparation of claim 1-8 in the medicine of preparation treatment bovine mastitis.
13. the application of biocide preparation according to claim 10 is characterized in that, the medicine of being addressed is used for injection in the cow breast.
14. the application of biocide preparation according to claim 10 is characterized in that, the medicine of being addressed is used for milch cow breast district outward.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031153887A CN1520881A (en) | 2003-02-13 | 2003-02-13 | Sterilizing preparation for preventing and curing bovine mastitis and preparing process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031153887A CN1520881A (en) | 2003-02-13 | 2003-02-13 | Sterilizing preparation for preventing and curing bovine mastitis and preparing process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1520881A true CN1520881A (en) | 2004-08-18 |
Family
ID=34284271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031153887A Pending CN1520881A (en) | 2003-02-13 | 2003-02-13 | Sterilizing preparation for preventing and curing bovine mastitis and preparing process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1520881A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007095830A1 (en) * | 2006-02-21 | 2007-08-30 | Beijing Dabeinong Animal Health Science And Technology Co., Ltd. | Powder perfusion agent used in the treatment of bovine mastitis and its preparing process |
| WO2009150171A1 (en) * | 2008-06-10 | 2009-12-17 | Profos Ag | Method of treatment of inflammatory diseases |
| CN100998873B (en) * | 2006-11-28 | 2010-11-03 | 中国农业大学 | Gone medicine for preventing and treating mammitis of animal |
| CN102150752A (en) * | 2010-12-20 | 2011-08-17 | 上海高科联合生物技术研发有限公司 | Method for preparing antimicrobial feed additive |
| CN102524558A (en) * | 2010-12-27 | 2012-07-04 | 内蒙古伊利实业集团股份有限公司 | Feed additive for treating dairy cattle recessive mastitis |
| CN101649311B (en) * | 2009-09-15 | 2012-10-10 | 吉林大学 | Preparation method of human lysozyme-antibacterial peptide Catesbeianin-1 fusion protein and application of same on preventing and curing cow mastitis |
| CN105169378A (en) * | 2015-08-12 | 2015-12-23 | 江苏绿科生物技术有限公司 | Preparation method of complex lysostaphin disinfectant |
| CN106117315A (en) * | 2016-07-19 | 2016-11-16 | 吉林大学 | Pentapeptide medical application in treatment S. aureus L-forms mammitis of cow |
| CN106188233A (en) * | 2016-07-19 | 2016-12-07 | 吉林大学 | A kind of polypeptide treating S. aureus L-forms mammitis of cow and preparation technology |
| CN109395068A (en) * | 2018-11-26 | 2019-03-01 | 浙江舒是生物科技有限公司 | A kind of refractory wound Special sterilizing liquid |
| CN112999337A (en) * | 2019-12-19 | 2021-06-22 | 昆山博青生物科技有限公司 | Biological enzyme disinfectant preparation and preparation method thereof |
| CN115212287A (en) * | 2022-07-12 | 2022-10-21 | 刘瑶 | Cow breast antibacterial peptide injection and preparation method and application thereof |
-
2003
- 2003-02-13 CN CNA031153887A patent/CN1520881A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007095830A1 (en) * | 2006-02-21 | 2007-08-30 | Beijing Dabeinong Animal Health Science And Technology Co., Ltd. | Powder perfusion agent used in the treatment of bovine mastitis and its preparing process |
| CN100998873B (en) * | 2006-11-28 | 2010-11-03 | 中国农业大学 | Gone medicine for preventing and treating mammitis of animal |
| WO2009150171A1 (en) * | 2008-06-10 | 2009-12-17 | Profos Ag | Method of treatment of inflammatory diseases |
| CN101649311B (en) * | 2009-09-15 | 2012-10-10 | 吉林大学 | Preparation method of human lysozyme-antibacterial peptide Catesbeianin-1 fusion protein and application of same on preventing and curing cow mastitis |
| CN102150752A (en) * | 2010-12-20 | 2011-08-17 | 上海高科联合生物技术研发有限公司 | Method for preparing antimicrobial feed additive |
| CN102524558A (en) * | 2010-12-27 | 2012-07-04 | 内蒙古伊利实业集团股份有限公司 | Feed additive for treating dairy cattle recessive mastitis |
| CN105169378A (en) * | 2015-08-12 | 2015-12-23 | 江苏绿科生物技术有限公司 | Preparation method of complex lysostaphin disinfectant |
| CN106117315A (en) * | 2016-07-19 | 2016-11-16 | 吉林大学 | Pentapeptide medical application in treatment S. aureus L-forms mammitis of cow |
| CN106188233A (en) * | 2016-07-19 | 2016-12-07 | 吉林大学 | A kind of polypeptide treating S. aureus L-forms mammitis of cow and preparation technology |
| CN106188233B (en) * | 2016-07-19 | 2019-07-05 | 吉林大学 | A kind of polypeptide that treating S. aureus L-forms mastitis for milk cows and preparation process |
| CN106117315B (en) * | 2016-07-19 | 2019-07-30 | 吉林大学 | Medical application of the pentapeptide in treatment S. aureus L-forms mastitis for milk cows |
| CN109395068A (en) * | 2018-11-26 | 2019-03-01 | 浙江舒是生物科技有限公司 | A kind of refractory wound Special sterilizing liquid |
| CN112999337A (en) * | 2019-12-19 | 2021-06-22 | 昆山博青生物科技有限公司 | Biological enzyme disinfectant preparation and preparation method thereof |
| CN115212287A (en) * | 2022-07-12 | 2022-10-21 | 刘瑶 | Cow breast antibacterial peptide injection and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1520881A (en) | Sterilizing preparation for preventing and curing bovine mastitis and preparing process thereof | |
| CN1209972C (en) | Sterilization formulation and wet tissue, preparation method and use | |
| CN1883275A (en) | A botanical antibiotic and application thereof | |
| CN1309304C (en) | Sterilizing gel, preparing method and application thereof | |
| RU2370259C1 (en) | Method of cow udder teat disease treatment in mechanised milking | |
| CN103828841B (en) | A kind of pharmaceutical composition and application thereof preventing and treating pebrine disease | |
| CN1125592C (en) | Compound lysostaphin enzyme disinfectant | |
| CN115192642B (en) | Preparation method and application of composite biological preparation with parasiticidal function and containing Brevibacillus laterosporus and fermented traditional Chinese medicine | |
| CN102552317B (en) | Iodine glycerol nipple infusion and preparation method thereof | |
| CN101708187A (en) | Dry powder preparation for preventing and controlling saprolegniasis of aquatic animals and preparation method thereof | |
| CN101683074A (en) | Pharmaceutical composition for disinfecting livestock and poultry environments and aquatic water bodies and preparation method thereof | |
| CN103893760A (en) | Bovine mastitis medicament-fast bacteria IgY and composite phage composition and preparation method and preparation thereof | |
| CN105560374A (en) | Compound preparation for treating dairy cow mammitis and preparation method thereof | |
| CN113616781A (en) | Cefalonin-containing preparation for treating dry-period mastitis of dairy cattle and preparation method thereof | |
| CN1327047A (en) | Method for cultivating variotin pecilocin with silkworm and medicinal use | |
| CN1137979C (en) | Composite lysostaphin washings and preparing method | |
| CN1593453A (en) | Sterilizing and bacteria inhibiting pharmaceutical composition and its formulation and preparation process | |
| CN1674932A (en) | New Bacteria Used to Treat Disease | |
| CN102008455A (en) | Freeze-dried powder preparation for curing bovine mastitis | |
| CN101843625B (en) | Compound ofloxacin injection for livestock and preparation method thereof | |
| RU2239445C1 (en) | Method for treating subclinical mastitis in lactating cows | |
| CN1911442A (en) | Lysostaphin freeze dried powder used for preventing and treating trauma surface infestation | |
| CN1613453A (en) | Azithromycin injection and its preparation | |
| CN1544087A (en) | Application of antalzyme and gene recombinate antalzyme 134 pure products in the preparation of birds and livestock diseases treating medicine | |
| Mushtaq et al. | Evaluation of combination of antibiotic with multienzyme preparation on bovine mastitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |